Dr Allison Goldfine

Dr Goldfine has completed her medical school training at the University of Pennsylvania, and internship and residency in Internal Medicine at the University of Massachusetts Medical Center. She then joined the Joslin Diabetes Center, where she completed her fellowship training in Endocrinology and Diabetes and continued her career to become the Head, Section of Clinical Research and Associate Professor of Medicine, Harvard Medical School.

Her research focus is in the mechanisms underlying type 2 diabetes and related disorders, leading to novel therapies. She was part of the steering committee of the multi-center studies to target inflammation with salicylate in the treatment of type 2 diabetes. She participated in and led Data Safety Monitoring Boards of industry and NIH sponsored trials. She served as a voting member on the Endocrine and Metabolic Disease Advisory Committee to the Food and Drug Administration, and served on the American Diabetes Association Practice Guideline Committee and Chaired the American Diabetes Association Clinical Research Grant Study Group. She has authored over 175 scientific original manuscripts, reviews, and chapters, and was the Section Editor for carbohydrate and lipid disorders of the recently published 14th Edition of Williams textbook in Endocrinology. In 2017, she joined Novartis Institute of Biomedical Research as Director, Translational Medicine for Cardiometabolic Disease, where she continues her work on drug discovery and development, and continues in patient care at Harvard’s Brigham and Women’s Hospital.